Treatment resistant schizophrenia - review and a call to action..pdf (671.6 kB)
0/0

Treatment resistant schizophrenia - review and a call to action.

Download (671.6 kB)
journal contribution
posted on 22.11.2019 by John Lally, Fiona Gaughran

Recovery rates in schizophrenia remain suboptimal with up to one-third resistant to standard treatments, a population prevalence of 0.2%. Clozapine is the only evidenced-based treatment for treatment resistant schizophrenia (TRS), yet there are significant delays in its use or it may not be trialled, potentially impacting the chance of recovery. Better outcomes with earlier use of clozapine may be possible. There is emerging evidence that early treatment resistance is not uncommon from the earliest stages of psychosis. In this review, we provide an update on TRS, its epidemiology and its management, with a specific focus on the optimal use and timing of clozapine and augmentation strategies for the one-third of patients who do not respond to clozapine.

Funding

Lundbeck, Otsuka, Sunovion, NHS Innovations/Janssen-Cilag, National Institute for Health Research Collaboration, NIHR Biomedical Research Centre.

History

Comments

This article has been published in a revised form in Irish Journal of Psychological Medicine https://doi.org/10.1017/ipm.2018.47. This version is free to view and download for private research and study only. Not for re-distribution, re-sale or use in derivative works. © copyright holder.

Published Citation

Lally J, Gaughran F. Treatment resistant schizophrenia - review and a call to action. Irish Journal of Psychological Medicine. 2018;35:1-13

Publication Date

27/11/2018

Publisher

Cambridge University Press

PubMed ID

30477599

Exports

Logo branding

Exports